96 related articles for article (PubMed ID: 26228901)
1. Longitudinal study of the substantia nigra in Parkinson disease: A high-field (1) H-MR spectroscopy imaging study.
Seraji-Bozorgzad N; Bao F; George E; Krstevska S; Gorden V; Chorostecki J; Santiago C; Zak I; Caon C; Khan O
Mov Disord; 2015 Sep; 30(10):1400-4. PubMed ID: 26228901
[TBL] [Abstract][Full Text] [Related]
2. MR Spectroscopy: A Longitudinal Biomarker for Substantia Nigra Pathology in Parkinson's Disease?
Öz G
Mov Disord; 2015 Sep; 30(10):1304-5. PubMed ID: 26184363
[No Abstract] [Full Text] [Related]
3. Proton MR Spectroscopy for Monitoring Pathologic Changes in the Substantia Nigra and Globus Pallidus in Parkinson Disease.
Wu G; Shen YJ; Huang MH; Xing Z; Liu Y; Chen J
AJR Am J Roentgenol; 2016 Feb; 206(2):385-9. PubMed ID: 26797368
[TBL] [Abstract][Full Text] [Related]
4. Usefulness of proton and phosphorus MR spectroscopic imaging for early diagnosis of Parkinson's disease.
Weiduschat N; Mao X; Beal MF; Nirenberg MJ; Shungu DC; Henchcliffe C
J Neuroimaging; 2015; 25(1):105-10. PubMed ID: 24325203
[TBL] [Abstract][Full Text] [Related]
5. Application of proton magnetic resonance spectroscopy on substantia nigra metabolites in Parkinson's disease.
Zhou B; Yuan F; He Z; Tan C
Brain Imaging Behav; 2014 Mar; 8(1):97-101. PubMed ID: 23955491
[TBL] [Abstract][Full Text] [Related]
6. Three-dimensional magnetic resonance spectroscopic imaging in the substantia nigra of healthy controls and patients with Parkinson's disease.
Gröger A; Chadzynski G; Godau J; Berg D; Klose U
Eur Radiol; 2011 Sep; 21(9):1962-9. PubMed ID: 21484351
[TBL] [Abstract][Full Text] [Related]
7. Metabolic changes in de novo Parkinson's disease after dopaminergic therapy: A proton magnetic resonance spectroscopy study.
Ciurleo R; Bonanno L; Di Lorenzo G; Bramanti P; Marino S
Neurosci Lett; 2015 Jul; 599():55-60. PubMed ID: 26007705
[TBL] [Abstract][Full Text] [Related]
8. Marked N-acetylaspartate and choline metabolite changes in Parkinson's disease patients with mild cognitive impairment.
Nie K; Zhang Y; Huang B; Wang L; Zhao J; Huang Z; Gan R; Wang L
Parkinsonism Relat Disord; 2013 Mar; 19(3):329-34. PubMed ID: 23238068
[TBL] [Abstract][Full Text] [Related]
9. Dopamine reduction in the substantia nigra of Parkinson's disease patients confirmed by in vivo magnetic resonance spectroscopic imaging.
Gröger A; Kolb R; Schäfer R; Klose U
PLoS One; 2014; 9(1):e84081. PubMed ID: 24416192
[TBL] [Abstract][Full Text] [Related]
10. Substantia nigra neuromelanin magnetic resonance imaging in de novo Parkinson's disease patients.
Reimão S; Pita Lobo P; Neutel D; Correia Guedes L; Coelho M; Rosa MM; Ferreira J; Abreu D; Gonçalves N; Morgado C; Nunes RG; Campos J; Ferreira JJ
Eur J Neurol; 2015 Mar; 22(3):540-6. PubMed ID: 25534480
[TBL] [Abstract][Full Text] [Related]
11. Usefulness of proton MR spectroscopy in the evaluation of temporal lobe epilepsy.
Thompson JE; Castillo M; Kwock L; Walters B; Beach R
AJR Am J Roentgenol; 1998 Mar; 170(3):771-6. PubMed ID: 9490972
[TBL] [Abstract][Full Text] [Related]
12. Progression marker of Parkinson's disease: a 4-year multi-site imaging study.
Burciu RG; Ofori E; Archer DB; Wu SS; Pasternak O; McFarland NR; Okun MS; Vaillancourt DE
Brain; 2017 Aug; 140(8):2183-2192. PubMed ID: 28899020
[TBL] [Abstract][Full Text] [Related]
13. Quantitative 1H magnetic resonance spectroscopy and MRI of Parkinson's disease.
O'Neill J; Schuff N; Marks WJ; Feiwell R; Aminoff MJ; Weiner MW
Mov Disord; 2002 Sep; 17(5):917-27. PubMed ID: 12360540
[TBL] [Abstract][Full Text] [Related]
14. Proton MRS of the unilateral substantia nigra in the human brain at 4 tesla: detection of high GABA concentrations.
Oz G; Terpstra M; Tkác I; Aia P; Lowary J; Tuite PJ; Gruetter R
Magn Reson Med; 2006 Feb; 55(2):296-301. PubMed ID: 16408282
[TBL] [Abstract][Full Text] [Related]
15. Parkinson's disease: in vivo metabolic changes in the frontal and parietal cortices in 6-OHDA treated rats during different periods.
Hou Z; Zhang Z; Meng H; Lin X; Sun B; Lei H; Fang K; Fang F; Liu M; Liu S
Int J Neurosci; 2014 Feb; 124(2):125-32. PubMed ID: 23931110
[TBL] [Abstract][Full Text] [Related]
16. Magnetic resonance spectroscopy: an in vivo molecular imaging biomarker for Parkinson's disease?
Ciurleo R; Di Lorenzo G; Bramanti P; Marino S
Biomed Res Int; 2014; 2014():519816. PubMed ID: 25302300
[TBL] [Abstract][Full Text] [Related]
17. Longitudinal changes in free-water within the substantia nigra of Parkinson's disease.
Ofori E; Pasternak O; Planetta PJ; Li H; Burciu RG; Snyder AF; Lai S; Okun MS; Vaillancourt DE
Brain; 2015 Aug; 138(Pt 8):2322-31. PubMed ID: 25981960
[TBL] [Abstract][Full Text] [Related]
18. Posterior cingulate metabolic changes occur in Parkinson's disease patients without dementia.
Camicioli RM; Korzan JR; Foster SL; Fisher NJ; Emery DJ; Bastos AC; Hanstock CC
Neurosci Lett; 2004 Jan; 354(3):177-80. PubMed ID: 14700725
[TBL] [Abstract][Full Text] [Related]
19. Proton Magnetic Resonance Spectroscopy Changes in Parkinson's Disease With and Without Psychosis.
Rodríguez-Violante M; Cervantes-Arriaga A; González-Latapí P; León-Ortiz P; de la Fuente-Sandoval C; Corona T
Rev Invest Clin; 2015; 67(4):227-34. PubMed ID: 26426588
[TBL] [Abstract][Full Text] [Related]
20. The contribution of cerebellar proton magnetic resonance spectroscopy in the differential diagnosis among parkinsonian syndromes.
Zanigni S; Testa C; Calandra-Buonaura G; Sambati L; Guarino M; Gabellini A; Evangelisti S; Cortelli P; Lodi R; Tonon C
Parkinsonism Relat Disord; 2015 Aug; 21(8):929-37. PubMed ID: 26077167
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
